Current treatments for allergic conjunctivitis are limited to anti-histamines and mast cell stabilizers that are often ineffective. The long-term goal of the proposal is to develop a new treatment for allergic conjunctivitis. We previously explored the anti-inflammatory and pro-resolution lipid mediators, the lipoxins, lipoxinA4 (LXA4) and lipoxin B4 (LXB4). Conjunctival goblet cell over secretion of mucus including the mucin MUC5AC is one of the symptoms of allergic conjunctivitis that include itching, conjunctival redness, tearing, and chemosis. Lipoxins have two modes of action. They block histamine over stimulation of goblet cell secretion and themselves activate a small amount of secretion to protect the ocular surface while the over secretion
